Real-World data on SVd combo for myeloma: will it hold up outside trials?

NCT ID NCT06933277

Recruiting now Knowledge-focused Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This observational study is collecting information on how well the combination of selinexor, bortezomib, and dexamethasone (SVd) works for adults with multiple myeloma who have already tried 1 to 3 other treatments. Researchers will track 159 patients for about 3 years to see how long the cancer stays under control. The goal is to understand the drug's effectiveness and safety in everyday medical practice, not in a strict research setting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selinexor, bortezomib, and dexamethasone (SVd)
What this could lead to: If successful, this study could provide real-world evidence on how well the SVd combination works for multiple myeloma patients outside of controlled clinical trials.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It does not test a new treatment but rather collects data on existing practice, so no new treatment benefits are guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Aou Careggi - Sod Ematologia
RECRUITING

Florence, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.